Gamble, SC and Chotai, D and Odontiadis, M and Dart, DA and Brooke, GN and Powell, SM and Reebye, V and Varela-Carver, A and Kawano, Y and Waxman, J and Bevan, CL (2007) Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene, 26 (12). pp. 1757-1768. DOI https://doi.org/10.1038/sj.onc.1209967
Gamble, SC and Chotai, D and Odontiadis, M and Dart, DA and Brooke, GN and Powell, SM and Reebye, V and Varela-Carver, A and Kawano, Y and Waxman, J and Bevan, CL (2007) Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene, 26 (12). pp. 1757-1768. DOI https://doi.org/10.1038/sj.onc.1209967
Gamble, SC and Chotai, D and Odontiadis, M and Dart, DA and Brooke, GN and Powell, SM and Reebye, V and Varela-Carver, A and Kawano, Y and Waxman, J and Bevan, CL (2007) Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene, 26 (12). pp. 1757-1768. DOI https://doi.org/10.1038/sj.onc.1209967
Abstract
Prohibitin (PHB) is a cell cycle regulatory protein, known to repress E2F1-mediated gene activation via recruitment of transcriptional regulatory factors such as retinoblastoma and histone deacetylase 1 (HDAC1). We previously identified PHB as a target protein of androgen signaling in prostate cancer cells and showed that downregulation of PHB is required for androgen-induced cell cycle entry in these cells. We now present evidence that PHB, which has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen receptor (AR)-mediated transcription and androgen-dependent cell growth. Depletion of endogenous PHB resulted in an increase in expression of the androgen-regulated prostate-specific antigen gene. The repression appears to be specific to androgen and closely related receptors, as it is also evident for the glucocorticoid and progesterone, but not oestrogen, receptors. In spite of interaction of PHB with HDAC1, HDAC activity is not required for this repression. Although AR and PHB could be co-immunoprecipitated, no direct interaction was detectable, suggesting that PHB forms part of a repressive complex with the AR. Competition with the co-activator SRC1 further suggests that formation of a complex with AR, PHB and other cofactors is the mechanism by which repression is achieved. It appears then that repression of AR activity is one mechanism by which PHB inhibits androgen-dependent growth of prostate cells. Further, this study implies that the AR itself could, by mediating downregulation of a corepressor, be involved in the progression of prostate tumours to the hormone refractory stage. © 2007 Nature Publishing Group All rights reserved.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | prohibitin; prostate cancer; androgen receptor; corepressor; cell cycle |
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Divisions: | Faculty of Science and Health Faculty of Science and Health > Life Sciences, School of |
SWORD Depositor: | Unnamed user with email elements@essex.ac.uk |
Depositing User: | Unnamed user with email elements@essex.ac.uk |
Date Deposited: | 26 Jun 2017 11:28 |
Last Modified: | 30 Oct 2024 19:21 |
URI: | http://repository.essex.ac.uk/id/eprint/8306 |